In primary hyperoxaluria type 1 (PH1), which is caused by mutations in alanine-glyoxylate aminotransferase (AGT), siRNA therapy in the mice and non-human primates has shown potential in reducing the expression of glycolate oxidase (GO) by targeting GO mRNA. The gene discussed is AGT; the disease is primary hyperoxaluria type 1.